[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GalenusRx, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100600081","pgx-medication-safety-reviews-of-persons-with-idd-100600081",false,"NCT07092852","PGx Medication Safety Reviews of Persons With IDD","Pharmacogenomic-Based Medication Safety Reviews of Persons With Intellectual and Developmental Disabilities","Inclusion Criteria:\n\n* Beneficiary with IDD\n* Reside in a CP Unlimited facility, NY state\n* At least 21 years of age\n\nExclusion Criteria:\n\n* Pregnant\n* Medical or physical abnormality that prevents cheek swab collection","ALL","21 Years",{"count":19,"type":20},700,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited. This initiative may help improve management of medications and overall health and well-being for participating individuals. Please note that in the context of the research being conducted, all information will remain confidential and deidentified for analyses.\n\nUnder the proposed study protocol, CP Unlimited, in partnership with pharmacists at GalenusRx, will implement and assess a comprehensive medication safety and PGx initiative. Almost three quarters of all clinical trials have eligibility criteria resulting in the exclusion of adults with IDD. This study will help address ongoing health practice disparity. As indicated above, the investigators are requesting the authorization of the guardian or representative, on behalf of the participant under their supervision, to enroll this individual in the proposed study because she\u002Fhe is currently prescribed medications or may eventually receive prescribed or over-the-counter medications. Hereinafter, the denomination \"he\u002Fshe, him\u002Fher, his\u002Fher or them\u002Ftheir\" will be used to refer to the individual with IDD.\n\nThe response to medication can be affected by variations in our genes and by other medications and various disease conditions. Information contained in our genes can vary from one patient to another patient and this can explain why we all can respond differently to medications. Genetic testing and a review of his\u002Fher medications can help to determine if the medication will work for him\u002Fher. PGx is how his\u002Fher genes affect the way he\u002Fshe responds to specific drugs. PGx can tell if he\u002Fshe is more or less likely to feel bad reactions to a drug, or if a drug is likely to benefit him\u002Fher and be safe for him\u002Fher to take. Knowing his\u002Fher genetic information and all medicines that he\u002Fshe is taking can help his\u002Fher pharmacist and his\u002Fher doctor find the combination of medicines that will work the best for him\u002Fher, now and in the future.",[24,25,26],"Intellectual Disability, Mild","Intellectual Disability, Mild to Moderate","Developmental Disability",[28,29,30,31],"Intellectual disabilities","Developmental disabilities","IDD","pharmacogenomics","NOT_YET_RECRUITING","2025-07-21",{"date":35,"type":36},"2025-07-30","ACTUAL",{"date":38,"type":20},"2025-08-01",{"date":40,"type":20},"2028-01-31",{"name":42,"class":43},"GalenusRx, Inc.","INDUSTRY",2,""]